The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploring potential biomarkers for FOLFIRI plus aflibercept as second-line treatment in patients with metastatic colorectal cancer.
 
Quy Pham Nguyen
No Relationships to Disclose
 
Junichi Matsubara
Honoraria - DAIICHI SANKYO COMPANY, LIMITED
 
Yuki Teramoto
No Relationships to Disclose
 
Chihiro Sato
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Daisuke Yamaguchi
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; MSD K.K; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Hiroshi Nakatsumi
Honoraria - Daiichi Sankyo; Viatris
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Meiji Seika Kaisha; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; Fujitsu Japan (Inst); H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical